SOUTH SAN FRANCISCO, Calif., Nov. 18, 2015 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will participate in a fireside chat discussion at the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2, 2015 at 11:00 a.m. ET in New York, NY.
The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The webcast will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.
About Veracyte
Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's Afirma® Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier (GEC) and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for nearly 155 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta™ Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer. Veracyte is developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.
Veracyte, Afirma, Percepta, the Veracyte logo, and the Afirma logo are trademarks or registered trademarks of Veracyte, Inc.
SOURCE Veracyte